Tredje AP fonden Cuts Stock Position in Catalent, Inc. (NYSE:CTLT)

Tredje AP fonden decreased its stake in shares of Catalent, Inc. (NYSE:CTLT) by 1.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,401 shares of the company’s stock after selling 444 shares during the quarter. Tredje AP fonden’s holdings in Catalent were worth $1,597,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Catalent by 1.1% during the first quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock valued at $1,151,872,000 after buying an additional 218,682 shares during the last quarter. Capital World Investors boosted its stake in Catalent by 6.1% during the 4th quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock valued at $857,264,000 after purchasing an additional 1,098,474 shares during the last quarter. Cadian Capital Management LP increased its holdings in shares of Catalent by 14.3% in the 4th quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock worth $272,473,000 after purchasing an additional 759,600 shares in the last quarter. Capital International Investors raised its stake in shares of Catalent by 1.2% in the fourth quarter. Capital International Investors now owns 2,994,467 shares of the company’s stock worth $134,541,000 after purchasing an additional 34,856 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Catalent during the fourth quarter valued at $116,021,000.

Insider Transactions at Catalent

In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the sale, the chief executive officer now owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the sale, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Matti Masanovich sold 2,993 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the completion of the transaction, the chief financial officer now owns 33,871 shares of the company’s stock, valued at $1,921,840.54. The disclosure for this sale can be found here. Insiders sold 13,409 shares of company stock worth $782,923 in the last three months. Corporate insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on CTLT shares. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Barclays increased their price objective on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. StockNews.com started coverage on shares of Catalent in a research report on Wednesday. They issued a “sell” rating for the company. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $58.08.

Catalent Stock Down 0.2 %

Shares of CTLT stock opened at $60.00 on Friday. The company has a 50 day simple moving average of $59.48 and a two-hundred day simple moving average of $57.21. The stock has a market cap of $10.86 billion, a P/E ratio of -9.84, a P/E/G ratio of 1.88 and a beta of 1.15. Catalent, Inc. has a 12 month low of $31.80 and a 12 month high of $61.20. The company has a current ratio of 2.52, a quick ratio of 1.77 and a debt-to-equity ratio of 1.35.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.